SOLANA BEACH, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Bridgetech Holdings International, Inc. , a company focused on maximizing the potential of emerging healthcare products and services in China and the U.S., today announced the execution of an exclusive license agreement in the field of human diagnostics with the University of Texas M. D. Anderson Cancer Center, ranked the nation's number one or number two cancer hospital by U.S. News and World Report's "America's Best Hospitals" survey for the 16th year in a row.
The initial product under this agreement is a prognostic to identify women who are at increased risk of developing recurrent cervical cancer. By allowing doctors to determine certain cell-mediated immune responses in a woman, they can then increase the frequency and types of testing done to ensure that any potential cervical cancer recurrence is detected as quickly as possible. Bridgetech has secured exclusive, worldwide distribution rights to this prognostic in the field of human diagnostics and will perform clinical trials through the Bridgetech CRO in order to facilitate obtaining regulatory approval in China.
"This is another significant product to augment our China strategy," said Michael Chermak, Chief Executive Officer of Bridgetech. "By adding M. D. Anderson Cancer Center's technology to the existing technologies of our partners like Johns Hopkins International and the Mary Crowley Medical Research Center, we are clearly establishing ourselves as the leader in Oncology and Women's health initiatives in China. M. D. Anderson was one of the nation's original three Comprehensive Cancer Centers and has long been recognized as one of the leaders in cancer treatment and research."
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the U.S. to capitalize on the demand for Western Healthcare in China. The Company is bringing emerging drugs, devices and diagnostics to China, with an initial focus on Oncology and Women's Health. In addition to the China healthcare market, Bridgetech is focusing on the areas of medical imaging and non-invasive surgery, nurse recruitment and training, and RFID based hospital asset management. For additional information, please visit http://www.bthi.com.
Forward-Looking Statements.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Bridgetech. Forward-looking statements may be identified by words such as "goals," "plans," "believes," "will," "expects" and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Investor Relations: Redwood Consultants, LLC 415-884-0348 Approved by: Bridgetech Holdings International, Inc. Thomas C. Kuhn III 678-428-3507
Bridgetech Holdings International, Inc.CONTACT: Redwood Consultants, LLC, +1-415-884-0348; or Thomas C. Kuhn III,Bridgetech Holdings International, Inc., +1-678-428-3507
Web site: http://www.bthi.com/
